OpGen

OpGen Forward P/E

The Forward P/E Ratio of OpGen (OPGN) as of Oct 22, 2026 is 15.46. In the previous year, Forward P/E Ratio was 30.45 — a change of -49.23% (lower).

Forward P/E

15.46

YoY

-49.23%

Last updated:

Forward P/E Ratio of OpGen is 2025 15.46 . Forward P/E Ratio of OpGen was 2024 30.45 . It decreases by -49.23% lower compared to the previous year.

The OpGen Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-27.32 USD
Jan 1, 2019
-29.34 USD
Jan 1, 2020
-13.93 USD
Jan 1, 2021
-10.49 USD
Jan 1, 2022
-9.80 USD
Jan 1, 2023
-11.18 USD
Jan 1, 2024
30.45 USD
Jan 1, 2025
15.46 USD
The OpGen Forward P/E history
YEARForward P/EYoY
15.46-49.23%
30.45-372.41%
-11.18+14.12%
-9.80-6.64%
-10.49-24.69%
-13.93-52.52%
-29.34+7.41%
-27.32+15.15%
-23.73+24.52%
-19.06-9.47%
-21.05-67.32%
-64.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Forward P/E Ratio of OpGen is 15.46 in 2025.

Forward P/E Ratio of OpGen changed from 30.45 to 15.46, representing a -49.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio OpGen since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's OpGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — OpGen

All Key Metrics — OpGen